In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
The Sponsor has considered the request of a label extension for a drug which is currently used off-label in MS patients.
Could modeling and simulation provide evidence that off-label administration delays disease progression without impacting safety parameters?
An in silico clinical trial was conducted using an agent-based model of innate and adaptive immune system as well as MS disease progression.
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
Design from Scratch an Influenza Vaccine
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved